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Background: Transforming growth factor-β1 (TGF-β1) is a potent regulator of cell growth and differentiation. TGF-β1
has been shown to be a key player in tissue remodeling processes in a number of disease states by inducing
expression of extracellular matrix proteins. In this study a quantitative proteomic analysis was undertaken to
investigate if TGF-β1 contributes to tissue remodeling by mediating mRNA splicing and production of alternative
isoforms of proteins.
Methodology/Principal findings: The expression of proteins involved in mRNA splicing from TGF-β1-stimulated
lung fibroblasts was compared to non-stimulated cells by employing isotope coded affinity tag (ICATTM) reagent
labeling and tandem mass spectrometry. A total of 1733 proteins were identified and quantified with a relative
standard deviation of 11% +/− 8 from enriched nuclear fractions. Seventy-six of these proteins were associated
with mRNA splicing, including 22 proteins involved in splice site selection. In addition, TGF-β1 was observed to
alter the relative expression of splicing proteins that may be important for alternative splicing of fibronectin.
Specifically, TGF-β1 significantly induced expression of SRp20, and reduced the expression of SRp30C, which has
been suggested to be a prerequisite for generation of alternatively spliced fibronectin. The induction of SRp20 was
further confirmed by western blot and immunofluorescence.
Conclusions: The results show that TGF-β1 induces the expression of proteins involved in mRNA splicing and RNA
processing in human lung fibroblasts. This may have an impact on the production of alternative isoforms of matrix
proteins and can therefore be an important factor in tissue remodeling and disease progression.Background
Remodeling of the airway wall, which involves altered
extracellular matrix deposition, is an important feature in
airway diseases such as asthma and chronic obstructive
pulmonary disease (COPD) [1]. This process has been
suggested to be associated with aberrant wound healing,
dependent on the presence of myofibroblasts [2,3]. Dif-
ferentiated myofibroblasts can be distinguished from
fibroblasts by de novo synthesis of α-smooth muscle actin
(α-SMA), increased expression of alternatively spliced
fibronectin (EDA) and assembly of stress fibers [4]. The
growth factor TGF-β1 has been shown to play an import-
ant role in the differentiation process inducing the* Correspondence: oskar.hallgren@med.lu.se
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reproduction in any medium, provided the orexpression of alternatively spliced fibronectin, which
leads to a subsequent increased expression of α-SMA [5]
and other cytoskeletal proteins [6]. In addition, TGF-β1 is
a potent inducer of various extracellular matrix compo-
nents such as collagen [7], fibronectin [8], and the pro-
teoglycans: biglycan [9,10] and versican [11-13].
During constitutive and alternative splicing of gene
products, splice site selection is regulated by altering ini-
tial binding of serine-arginine-rich splicing factors (SR
proteins) to pre-mRNA. These factors contain an
N-terminal RNA recognition motif that allows binding
to pre-mRNA and a C-terminal serine-arginine-rich do-
main that mediates protein-protein interactions. Differ-
ent exon-splicing enhancers and silencers are recognized
by specific subsets of SR proteins [14], which include
SRp20, SRp30a (ASF/SF2) SRp30c, 9 G8, SRp40, SRp55,
SRp70, SRp75, and SC35 [15-18]. The ratio of different
SR proteins and the presence of exon-splicing enhancersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of splicosomal proteins. SR proteins generally have nu-
clear localization but some members such as ASF/SF2,
9 G8, and SRp20 also function as mRNA transporters
between nucleus and the cytoplasm [19]. The activity of
SR proteins is tightly regulated via dynamic events of
phosphorylations and dephosphorylations in different
domains of the proteins [20]. The phosphorylation pat-
tern of SR proteins not only influence their activity and
function but also play a role in sorting SR proteins
within the nucleus [21]. Moreover, hypo-phosphorylation
of one domain of SR proteins serves as a nuclear export
signal [22].
One important aspect of TGF-β1-driven myofibroblast
differentiation is the exon inclusion of EDA in fibronec-
tin [23], a process that is not fully understood. However,
induced expressions of the splicing factors SRp40,
SRp20, or ASF/SF2 have been suggested to stimulate in-
clusion of EDA suggesting that splice site selection is
regulated by quantitative changes in multiple factors
[24,25]. Several other matrix molecules have been
shown to have different splice variants such as biglycan
[26], versican [27], decorin [28], and collagen [29]. The
exact role of these splice forms has not yet been
established.
To investigate the mechanism of TGF-β1-induced al-
ternative splicing, we employed isotope coded affinity tag
(ICATTM) reagent labeling and tandem mass spectrom-
etry [30] to identify nuclear proteins and characterize the
changes in their expression upon TGF-β1 stimulation
and focus on proteins involved in the splicing process.
We were able to provide a detailed quantitative expres-
sion pattern of 76 proteins involved in mRNA splicing
and RNA processing. The results showed that TGF-β1
altered the relative expression of serine and arginine-rich
splicing factors that control splice site selection and pro-
mote alternative splicing.Results
TGF-β1 induces myofibroblast-like characteristics in
fibroblasts
TGF-β1 stimulation for 24 h increased the immuno-reactivity
for α-SMA in human embryonic lung fibroblasts (HFL-1)
cells, which was accompanied by a change in phenotype
as shown by immunofluorescence (Figure 1A). These
results were further confirmed by western blot that
showed a significant two-fold increase of α-SMA upon
TGF-β1 stimulation for 48 h (P< 0.05) (Figure 1B). Fol-
lowing TGF-β1 stimulation HFL-1 cells also had an
increased immuno-reactivity for prolyl 4-hydroxylase
(Figure 1C), which catalyzes post-translational formation of
proline to 4-hydroxyproline in collagens. These results
could not fully be confirmed by western blot, whichshowed a two-fold increase after 48 h (P< 0.06)
(Figure 1D).
TGF-β1 significantly increased the expression of both
fibronectin and EDA fibronectin. However, following
TGF-β1 stimulation the relative ratio between EDA fibro-
nectin and fibronectin was significantly increased over
time as shown by q-PCR (Figure 2A). This was con-
firmed by western blot showing that TGF-β1 increased
the relative expression of EDA fibronectin compared to
fibronectin from 269% at 24 h to (P< 0.01) to 526% at
48 h (P< 0.001) (Figure 2B). These data show that TGF-
β1 may induce myofibroblast differentiation and this is
accompanied by an altered splicing pattern, exemplified
by the increase in alternatively spliced isoforms of
fibronectin.
Strategy for identification and relative quantification of
nuclear proteins
To address the question whether TGF-β1 stimulation
affects nuclear proteins that are involved in the splicing
process, we employed isotope coded affinity tag
(ICATTM) reagent labeling and tandem mass spectrom-
etry. Our experiments showed that the expression of
EDA fibronectin increased from 6 to 48 h of TGF-β1
stimulation (Figure 2A), which indicates that an alterna-
tive splice site selection was induced after 24 h. We
therefore decided to examine the expression of nuclear
proteins at this time point. Figure 3 shows a schematic
overview of the workflow used for the identification and
relative quantification of proteins in the nuclear fractions
[30-32]. Around 2500 proteins were identified in mul-
tiple LC-MS/MS experiments. This list was reduced to
approximately 2000 unique proteins after consolidating
the peptide-protein assignments. However, approxi-
mately 1,700 of these could be quantified after the
proper normalization of the relative abundances of
‘heavy’ and ‘light’ ICATTM reagent labeled peptides. After
classifying the proteins based on gene ontology [33], 76
proteins involved in pre-mRNA splicing and RNA pro-
cessing were selected and divided into 13 functional
groups as shown in Figure 4 and in Additional file 1:
Table S1. The most abundant group was classified as het-
erogeneous ribonucleoproteins and contained 19 pro-
teins (hnRNP). The second most abundant group (12
proteins) was proposed to be involved in splice site selec-
tion and the third most abundant group, containing 10
proteins, was classified as splicing factors. Nineteen pro-
teins were subunits of the snRNPs or associated with the
U1, U5, or U4/U6 snRNPs. In addition, helicases and
peptidyl-prolyl cis-isomerases were detected. The relative
standard deviation (RSD) was calculated from all ratios
of the total list of identified proteins matched by more
than one peptide and the average of this error was found
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Figure 1 TGF-β1 induces the expression of the α-SMA and prolyl-4-hydroxylase. Human embryonic lung fibroblasts (HFL-1), incubated with
or without TGF-β1 (10 ng/mL) for 24 h, were immunostained using antibodies against α-SMA (A) and prolyl-4-hydroxylase (C). Scale bars represent
50 μm. The α-SMA (B) and prolyl-4-hydroxylase (D) expression at 6, 24, and 48 h was examined by western blot and bands were quantified with
densitometry. Presented values are the intensity of each band relative to loading control: GAPDH. Each value represent mean and SEM from four
individual experiments. *P< 0.05.
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of RSDs was less than 20%.
Additional file 1: Table S1 show the relative expression
levels (defined as TGF-β1 stimulated/control) of the indi-
vidual splicing related proteins calculated from four
unique experiments from independent cell cultures and
ICAT workflow runs.
Interestingly, TGF-β1 altered the expression of splicing
factors and additional proteins involved in splice site se-
lection. The expression of splicing factor U2 small nu-
clear ribonucleoproteins auxiliary factor (65 kDa)
(U2AF), and SRp20 were significantly increased by
TGF-β1 (1.09-fold and 1.24-fold, respectively) (Add-
itional file 1: Table S1). Furthermore, splicing factor
SRp30c was significantly repressed (0.79-fold) following
TGF-β1 stimulation. The relative expression of all pro-
teins involved in splice site selection (grouped as splicesite selection and splicing factors in Additional file 1:
Table S1) was further statistically analyzed as shown in
Figure 5. The data show that TGF-β1 significantly
repressed the expression of SRp30C labeled ‘2d’ com-
pared to all other splicing factors except SRp 9 G8 (2b).
SRp20 (2c) was significantly increased compared to
SRp1 (2a) and SRp30c (2d). When comparing the levels
of SRp20 with SRp30c, the actual difference between
these two splicing factors was 1.6-fold. Several other
proteins were significantly changed upon TGF-β1 stimu-
lation, such as RNA-binding region containing proteins,
U5 snRNP 100 kDa protein, U5 small nuclear ribonu-
cleoprotein 200 kDa, CGI-59 protein, and Cisplatin re-
sistance-associated over expressed protein. In addition
the expression of the helicase Nucleolar RNA helicase II
(Nucleolar RNA helicase Gu) was also significantly
different.
Figure 2 TGF-β1 increases the relative expression of alternative splice forms of fibronectin. HFL-1 cells were incubated with or without
TGF-β1 (10 ng/mL) for 6, 24, and 48 h and the relative expression of fibronectin-EDA compared to fibronectin were measured by q-PCR and
western blot. (A) The relative expression of EDA fibronectin was compared to fibronectin by q-PCR. Each value represents mean and SEM from
three individual experiments. (B) The relative expression of fibronectin-EDA compared to fibronectin was measured by western blot. Bands were
quantified with densitometry and were related the loading control: GAPDH. Each value represents mean and SEM from four individual
experiments. *P< 0.05. During the ECL development the 48-h fibronectin band became saturated. *P< 0.05, **P< 0.01, ***P< 0.001.
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Phosphorylated SR proteins from TGF-β1-stimulated
HFL-1 cells were analyzed by western blots using an
antibody as previously described [34,35]. This antibody
detects a conserved phospho-epitope on SR proteins,
which does not coincide with absolute protein levels.
We detected a complete array of SR proteins, including
SRp75, SRp55, SRp40, SRp20, and an additional band
that corresponds to proteins that co-migrate around
30 kDa (ASF/SF2, SC35, or SRp30c) [35] (Figure 6A
and Table 1). TGF-β1 induced an increase of all the
detected SR proteins. A moderate increase was observed
at 6 h but at 24 and 48 h the increase was more pro-
nounced (Figure 6A and B). Moreover, TGF-β1 triggered
a 3.2-fold increase of the SRp75 at 24 h (P< 0.05) that
was preserved at 48 h. SRp55 was 3.0-fold increased at
24 h (P< 0.05) and then slightly decreased at 48 h.
SRp40 was continuously increased over time from a 3.5-
fold elevation at 24 h (P< 0.05) to a 4.2-fold increase at
48 h. There was 3.4-fold increase of the band that was
detected at 30 kDa at 24 h (P< 0.05) and the same in-
crease was retained at 48 h. SRp20 was elevated 8.1-foldcompared to untreated cells at 24 h (P< 0.05) which
declined to 6.7-fold at 48 h (Figure 6B). To verify the
TGF-β1-induced increase of SRp20 we performed separ-
ate western blots using an antibody that recognizes the
actual protein and does not discriminate between phos-
phorylated and non-phosphorylated variants (Figure 6C).
With this antibody there was a 1.8-fold increase of
SRp20 at 24 h (P< 0.05) and a 2.4-fold increase at 48 h
(P< 0.05), which supports the results from Additional
file 1: Table S1.
Cellular localization of SR proteins and SRp20 following
TGF-β1 stimulation
Next, we investigated how TGF-β1 stimulation influ-
enced the cellular localization of SR proteins and SRp20
by immunofluorescence. The staining pattern of the spli-
cing factors, using the anti-phospho SR proteins anti-
body, was exclusively nuclear (Figure 7). The staining
was more intense at 48 h but this could surprisingly not
be observed at 24 h of TGF-β1 stimulation compared to
untreated cells. In addition the staining at 48 h was more
speckled but not to the same extent at 24 h TGF-β1
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Nuclear Purification
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Figure 3 Schematic illustration of the workflow. Cell nuclei from
TGF-β1 stimulated HFL-1 cells were isolated and disrupted by
sonication followed by ICAT labeling and trypsin digestion. The
tryptic peptides were separated by strong cation exchange
chromatography and the ICAT labeled (cysteine-containing) peptides
were affinity purified on an avidin column. The captured fractions
were split in two. Half of the material was analyzed by online ESI LC-
MS/MS on a Qstar(R) Pulsar System and half of the material was
analyzed in HPLC coupled to an off-line MALDI target fraction
collector and analyzed on AB 4700 Proteomics Analyzer.
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was mainly nuclear in untreated cells and after 24 h of
TGF-β1 stimulation although some faint extra-nuclear
staining also could be observed (Figure 8). However, after
48 h TGF-β1 stimulation SRp20 was both located intra-
and extra-nuclear and in addition the staining was more
speckled and intense.
Discussion
In the present study the role of TGF-β1 on the expres-
sion levels of proteins involved in mRNA splicing and
RNA processing was examined with a quantitative prote-
omic approach. We observed that TGF-β1 altered therelative ratio of splicing factors that may be important
for alternative splicing of proteins. One such example
was that TGF-β1 affected the levels of splicing factors
possibly of importance in EDA fibronectin production,
suggesting a regulatory role in myofibroblast differenti-
ation. These results indicate that TGF-β1 may contribute
to tissue remodeling and disease progression by meditat-
ing mRNA splicing and the production of alternative iso-
forms of proteins.
TGF-β1 plays an important role in normal wound heal-
ing but is also a central player in the development of fi-
brosis and tissue remodeling. TGF-β1 has been shown to
induce the production of various extracellular matrix
components, such as collagen [7], fibronectin [8], and
proteoglycans [11-13,36], that are elevated during dis-
ease. In the present study we verified that TGF-β1 trig-
gered a cellular phenotypic switch of lung fibroblasts
resulting in a myofibroblast-like phenotype that express
α-SMA, as previously described [37]. In addition, TGF-
β1 induced production of alternative splicing variants of
fibronectin. These events were accompanied by altera-
tions in the relative ratios of proteins involved in mRNA
splicing and RNA processing. Alternative splicing is an
important aspect of gene regulation and results in dra-
matic biological consequences. It has been estimated that
as much as 60% of genes undergo alternative splicing
[38] and 15% of human genetic diseases are caused by
mutations that destroy functional splice sites or generate
new sites [39]. Splicing of mRNA is carried out by the
spliceosome, a large nuclear macromolecular complex of
five small nuclear ribonucleic particles (snRNPs) and
50–100 polypeptides [40]. In the current study TGF-β1
stimulation altered the relative expression of 76 proteins
involved in RNA splicing and processing which indicate
that TGF-β1 may be an important regulator for this
process.
The ICAT results were verified by western blots that
showed a general increase of phosphorylated SR proteins
following TGF-β1 stimulation. The increased levels of
SRp20, SRp40, and SRp75 from the ICAT experiments
were consistent with the western blots (Table 1 and
Additional file 1: Table S1). SRp20 was found to be
induced by both ICAT and western blot using the antibody
detecting the absolute protein level. However, when using
the antibody that recognized phospho-epitopes of SRp20
then it was further induced. These data may suggest that
TGF-β1 may influence the level of phosphorylation of SR
proteins which is important for their function and
localization. These results were further confirmed with im-
munofluorescence that indicated an increase of SRp20 ac-
companied by extra-nuclear localization. Some SR
proteins, including SRp20, have in addition to their nuclear
functions also been shown to be involved in shuttling
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Figure 4 Classification according to molecular function of the proteins involved in pre-mRNA splicing. Following TGF-β1 stimulation
(10 ng/mL) 76 ICAT labeled proteins involved in pre-RNA splicing and RNA processing were identified. The most abundant groups of proteins
identified were proteins involved in RNA processing, splicing factors, and other proteins involved in splice site selection.
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that detect phosphorylated SR proteins then the staining
was strictly nuclear which may seem contradictory as
SRp20 is one of the protein targets for the antibody. How-
ever, it has been shown that hypo-phosphorylation is a sig-
nal for nuclear export which may explain the difference in
staining pattern.
There was a discrepancy in the expression levels of
SRp55 as it was induced in the western blots and
repressed in the ICAT dataset. A possible explanation for
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Figure 5 Relative change of proteins involved in splice site selection.
splicing factors following TGF-β1 stimulation (10 ng/mL) was calculated. Th
protein, is visualized as a color grid. Black box represents no statistically sig
at least P <0.05. 1a denotes: RNA-binding region containing protein 2, 1b:
factor, 1c: splicing factor 3 subunit 1, 1d: splicing factor 3A subunit 3, 1e: sp
auxiliary factor 35 Kda subunit related-protein 2, 1 g: splicing factor 3A subu
RNA- and DNA-binding protein (P54(Nrb)), 1j: FUSE binding protein 2, 1 k: s
1 l: splicing factor 3B subunit 793. 2a denotes: splicing factor, arginine/serin
9 G8, 2c: splicing factor, arginine/serine-rich 3 (pre-Mrna splicing factor SRP
auxiliary factor 35 Kda subunit), 2e: splicing factor U2AF 65 Kda subunit, 2f:
2 g: splicing factor, arginine/serine-rich 6 (pre-Mrna splicing factor SRP55), 2
SRP75), 2i: splicing factor arginine/serine-ich 5 (HRS) (pre-Mrna splicing factoconserved phospho-epitope and does not coincide with
absolute protein levels. In addition, TGF-β1 changed the
expression of several other proteins such as U5 associated
proteins, U5 small nuclear ribonucleoprotein 200 kDa,
U5 snRNP 100 kDa protein, and helicases, RNA-
dependent helicase p72 and the RNA helicase II/Gu pro-
tein, all which have been shown to induce conformational
changes in the spliceosome [41-43]. This suggests that
TGF-β1 also can affect the splicing process via conform-
ational changes of the spliceosome. In addition, we found
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r SRP40).
Figure 6 Western blot analysis of SR proteins after stimulation by TGF-β1. (A) HFL-1 cells were stimulated with TGF-β1 (10 ng/mL) for 6, 24,
and 48 h. Cell homogenates were separated by SDS-PAGE and after blotting the proteins were detected with an antibody that recognizes a
phospho-epitope on a wide range of SR proteins. Bands were visualized by a fluorescent secondary antibody and analyzed on OdysseyW FC
imaging system. The most prominent bands represent the splicing factors SRp75, SRp55, SRp40, SRp30a-c, and SRp20. #The band migrating
around 30-kDa could consists of several splicing factors with the approximate molecular weight of 30 kDa. (B) Bands were quantified by
densitometry and were then related to their respective GAPDH loading control. Values show the relative expression between TGF-β1-stimulated
cells compared to untreated. (C) The expression of SRp20 at 6, 24, and 48 h was examined by western blot and bands were quantified with
densitometry. The antibody is not directed against phospho-epitope of the protein. Presented values are the intensity of each band relative to the
intensity of the loading control: GAPDH. Each value represent mean and SEM from four individual experiments. *P< 0.05.
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inhibits binding of the splicing factors to the immature
mRNA [44]. Splicing of mRNA is a complex operation
which involves the activity of multiple proteins. It has
been suggested that the relative ratios of proteins
involved in selection of splice-sites and splicing factors
may be determinants of splice site selection and alterna-
tive splicing [45,46]. The experimental setup in this
study enabled direct comparison of relative expression
levels within these groups of protein (Figure 5). Our
data support the idea that relatively small up- and
down-regulation of different splicing factors may regu-
late splicing of a specific mRNA.The ICAT experiments were chosen at a time-point
where the initial changes in fibronectin splicing pattern
was observed (t = 24 h) and thus, the quantification of
the splicing factors and hnRNPs was made at a time
point where alternative spliced sites were selected. We
found that the expression of SRp20 was induced and that
the expression of SRp30c was repressed. The role of
SRp30c in alternative splicing of fibronectin is unclear.
However, SRp20 has previously been shown to promote
alternative splicing of EDB in fibronectin when induced
and to inhibit EDA splicing in chondrocytes [26,47]. In
HeLa cells both the levels of EDA+ and EDA- fibronec-
tin mRNA were suppressed when over expressing SRp20,
Table 1 Comparison of TGF-β1-induced fold change from









aWestern blot were performed using an antibody that recognizes a
phospho-epitope on SR proteins and not absolute protein levels.
bP< 0.05.
cThe band at around 30-kDa could consist of several splicing factors, all with
the approximate molecular weight of 30 kDa.
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(ASF/SF2) [48,49], 9 G8 [48], and SRp40 [25,47] have
positive effects on EDA inclusion. We propose that
TGF-β1 mediates differential splicing of fibronectin by
altering the relative expression and/or phosphorylation
pattern of several of these splicing factors, which interact
to promote alternative splicing. During the remodeling
processes, EDA and EDB are included into the mature
mRNA to generate splice isoforms [50]. These alternative
splice isoforms promote cell attachment and facilitates
cell migration [51] and have been found to be elevated in
fibrotic tissue [52] and malignant human tumors [53].Figure 7 Cellular localization of SR proteins. HFL-1 cells were incubated
localization of SR proteins was examined with immunofluorescence using a
for SR proteins are shown in red and nucleus are visualized by DAPI (blue).
nucleus. Arrowheads show speckles with more intense staining.TGF-β1 is known to induce an increase of EDA and EDB
fibronectin in both fetal and adult fibroblasts [54]. Collect-
ively, these data indicate that TGF-β1 not only stimulates
myofibroblast differentiation and the expression of ECM
proteins, but also may contribute to alternative splicing.
Conclusions
In summary, we have shown that TGF-β1 may alter the
expression levels of the splicing factors that regulate al-
ternative splicing of matrix proteins. This may have an
impact on the production of alternative isoforms of
matrix proteins and suggests a novel mechanism of how
TGF-β1 mediates tissue remodeling and disease
progression.
Methods
Cell culturing and TGF-β1 stimulation
Human embryonic lung fibroblasts (HFL-1) (ATCC,
Manassas, VA, USA) were sub-cultured in Eagles mini-
mum essential medium (EMEM) supplemented with 1%
glutamine and 10% fetal calf serum (FCS) and PEST. Be-
fore experiments cells were grown to confluency and
were starved overnight in Dulbecco’s modified Eagle
medium (DMEM) with 0.4% FCS. Cells were washed in
PBS and were then incubated with or without TGF-β1
(10 ng/mL) (R&D Systems Abingdon, UK) for the time-
points indicated in the figures. Experiments were per-
formed in passage 17–22.for 24 and 48 h with or without TGF-β1 (10 ng/mL). The intracellular
n antibody that recognizes a phospho-epitope on SR proteins. Staining
Immune-reactivity for SR proteins was exclusively observed in cell
Figure 8 Cellular localization of SRp20. HFL-1 cells were incubated for 24 and 48 h with or without TGF-β1 (10 ng/mL). The intracellular
localization of SRp20 was examined with immunofluorescence using an antibody that is not directed against phospho-epitope of the protein.
Staining for SRp20 are shown in red and nucleus are visualized by DAPI (blue).
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Cells were grown under standardized conditions with or
without TGF-β1 (10 ng/mL) for 6, 24, or 48 h and whole
cell lysates were prepared using lysis buffer (50 mM
Tris–HCl, 500 mM NaCl, 1% NP-40, 10% glycerol,
10 mM MgCl2, pH 7.4) containing the protein inhibitor
cocktail complete mini (1 mM PMSF, 1 μg/mL Aproti-
nin, 1 μg/mL Pepstatin, 1 μg/mL Leopeptin, Roche,
Manheim, Germany). Samples were solubilized in
Laemmli’s buffer and equal amounts of total protein
(10 μg) were loaded and separated by electrophoresis on
4–12% Bis-Tris Gels (Invitrogen, Gibro, Carlsbad, CA,
USA). The proteins were blotted to PVDF membranes
(Immobilon-P Transfer Membrane, Millipore Corpor-
ation, Billerica, MA, USA). Membranes were incubated
with antibodies against: a-SMA (Abcam, Cambridge, UK),
prolyl 4-hydroxylase (Acris antibodies, Hiddenhausen,
Germany), fibronectin (Dako, Glostrup, Denmark), EDA-
fibronectin (Abcam, Cambridge, UK), GAPDH (Santa
Cruz Biotechnology, Inc. Santa Cruz, CA, USA), Phospho-
SR proteins (Zymed Laboratories, San Francisco, CA,
USA), and SRp20 (Zymed Laboratories, San Francisco,
CA, USA). Bound antibodies were visualized by peroxid-
ase-conjugated secondary antibodies and enhanced lumi-
nescence (AmershamTM western blotting Detection
Reagents, GE Healthcare, Uppsala, Sweden) with exception
for the blot against phospho-SR proteins where Dy-light
800 nm conjugated secondary antibodies (Cell SignalingTechnology Inc., Boston, MA, USA) was used. The lumi-
nescence/fluorescence signal was detected on OdysseyW
FC imaging system (LI-COR Biosciences, Lincoln, NE,
USA). Exposure times were standardized so that all sam-
ples were treated the same way for each antibody. Individ-
ual bands were quantified with densitometry using the
Quantity One software version 4.6.1 (BIORAD Laborator-
ies, Hercules, CA, USA). Data are based on four individual
sets of experiments.Immunofluorescence
Fibroblasts (7000/well) were grown overnight on cham-
ber slides and were then incubated with or without
TGF-β1 24 and 48 h. Cells were then fixed in 4% formal-
dehyde for 15 min and permeabilized with 0.1% Triton
X for 30 min. After blocking in 2% BSA-TBS containing
5% goat serum (Vector laboratories, Burlingame, CA,
USA) for 30 min, cells were incubated with primary
antibodies against: a-SMA (Abcam, Cambridge, UK),
prolyl 4-hydroxylase (Acris antibodies, Hiddenhausen,
Germany), Phospho-SR proteins (Zymed Laboratories,
San Francisco, CA, USA), and SRp20 (Zymed Laborator-
ies, San Francisco, CA, USA) and with secondary anti-
bodies: Alexafluor 555-conjugated goat anti-mouse
antibody and Alexafluor 555-conjugated goat anti-rabbit
antibody (both from Molecular Probes Invitrogen,
Eugene, OR, USA). To stain nuclei, cells were incubated
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USA). Glasses were mounted with mounting media
(Dako, Glostrup, Denmark) and photographed using a
TE2000-E fluorescence microscope (Nikon, Tokyo,
Japan) equipped with a DXM1200C camera (Nikon).
RNA extraction and cDNA synthesis
Cells were grown under standardized conditions with or
without TGF-β1 (10 ng/mL) for 6, 24, or 48 h. Total
RNA was isolated from cells using RNeasy (Qiagen,
GmBH, Hilden, Germany) according to the manufac-
turer´s instructions. The quantity of RNA was measured
by spectrophotometry using a NanoDrop ND-100 (Nano
Drop Technologies, Delaware, MD, USA). Total RNA
(1 μg) was reverse-transcribed using superscript II
according to the manufacturer’s manual (Invitrogen,
Carlsbad, CA, USA) and stored at −70°C.
Real-time RT-PCR
Five μL of cDNA (diluted 1:250) was mixed with 15 μL
SYBR-green mixture (PE Biosystems, Foster City, CA,
USA) and amplified by real-time RT-PCR using Strata-
gene MX3005P QPCR system (Agilent Technologies,
Santa Clara, CA, USA). Initially the samples were held
for 2 min at 50°C then for 10 min at 95°C; they were
then cycled for 40 cycles of 30 s at 95°C, 1 min at 58°C,
and 1 min at 72°C. Each sample was analyzed in tripli-
cate. Reactions were performed using MX3000P 96-well
plates (Agilent Technologies, Santa Clara, CA, USA). All
primers were constructed using the online Primer 3 pro-
gram (http://frodo.wi.mit.edu/primer3/) and they were
ordered from A/S DNA Technology (Risskov, Denmark).
The following primers were used. Fibronectin forward:
CGA TCA CTG GCT TCC AAG TT, and reverse: TCC
GAG CAT TGT CAT TCA AG. Fibronectin-EDA for-
ward: AAT CCA AGC GGA GAG AGT CA, and reverse:
CGT AAA GGG CTC AGC TCA AG. S18 forward:
CGA ACG TCT GCC CTA TCA AC, and reverse: TGC
CTT CCT TGG ATG TGG TA. All primers were tested
for specificity by sequence alignment in the PubMed nu-
cleic acid database (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). Data are based on three individual sets of
experiments.
Purification of nuclei
The nuclei were purified according from a protocol pre-
viously described [55]. Briefly, the cells were harvested in
60 mM KCl, 15 mM NaCl, 0.15 mM Spermine, 0.5 mM
Spermidine, 15 mM Hepes, and 14 mM Mercaptoetha-
nol supplemented with 0.2% (v/v) Nonidet p40, aprotinin
(1 μg/mL), leupeptin (1 μg/mL), pepstatin A (1 μg/mL),
PMSF (10 μg/mL) and 0.3 M sucrose. The cell suspen-
sion was then homogenized with 60 strokes at 2,000 rpm
(Labortechnik, Berlin, Germany) and the homogenatewas filtered with 100 μm filter paper (Schleicher&Schuell,
Dassel, Germany). The nuclei were counted in a Bürker
chamber and the purity was assessed and protein content
was determined by Bradford protein reagent kit (Pierce,
Rockford, IL, USA).Labeling with the acid-cleavable ICATTM reagent and
isolation of cysteine containing peptides
Fibroblast nuclei were lysed in a buffer containing 6 M
Guanidium-HCl (pH 8.5), 1% Triton X-100, and 50 mM
Tris HCl, followed by sonication. Starting with 500 μg for
control and TGF-β1 stimulated, each sample was reduced
by adding 10 μl of 50 mM TCEP (Tris(2-carboxyethyl)
phosphine) and boiled for 10 min. The samples were
allowed to cool and the acid cleavable ICATTM reagent
(all the materials in this section are from the ICATTM
reagent kit Applied Biosystems, Framingham, MA, USA)
was added: the light reagent to the control and heavy re-
agent containing nine 13 C to the TGF-β1-treated sample.
Alkylation was allowed to complete for 2 h, at 37°C. The
two samples are combined and acetone precipitated in
order to remove the guanidium-HCl and the unreacted
ICATTM reagent. The pellet was dissolved in a buffer
consisting of 50 mM Tris (pH 8.5), 5 mM CaCl2, and
10% acetonitrile. Trypsin was added at a 1:40 enzyme/
substrate ratio in two additions once at the start of the
digestion and once more, 2 h later. Digestion was com-
pleted at 37°C overnight.
Following digestion the sample was diluted into 25%
acetonitrile, pH 3.0 in order to reduce the buffer concen-
tration below 10 mM. The resulting peptide mixture was
injected to a PolyLC (4.6 × 100 mm Polysulfoethyl A)
SCX column on Vision workstation (Applied Biosystems,
Framingham, MA, USA) at a flow rate of 1 mL/min
using a binding buffer (buffer A) 10 mM KH2PO4, 25%
acetonitrile, pH 3 and an elution buffer (buffer B) of
350 mM KCL, 10 mM KH2PO4, 25% acetonitrile, pH 3.
The gradient was 0% B to 10% B in 2 min, 20% B in
15 min, 45% B in 3 min, 100% B in 10 min, and an add-
itional 8 min hold at 100% B. Twenty-three SCX frac-
tions of 1.5 mL volume were collected.
The pH was adjusted for each SCX fraction to 7.2 with
10× PBS buffer (pH 10) and injected to the avidin affinity
column as prescribed by the manufacturer (Applied Bio-
systems, Framingham, MA, USA). Cysteine-containing
peptides bound to the avidin column were washed three
times: 1 mL of Wash 1, 1 mL of Wash 2, and 1 mL of
de-ionized water. Elution of the cysteine-containing pep-
tides was performed with 800 μL of avidin elution buffer.
The samples were then concentrated by a speed-vac to
dry, cleaved with the ICATTM cleaving reagent contain-
ing 95% TFA and concentrated again to remove the
cleaving reagent. The samples were then taken up in 2%
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MS and MS/MS analysis.
Protein identification and quantification by LC-MS and
-MS/MS
Avidin purified SCX fractions were subjected to
MALDI and ESI HPLC-MS and MS/MS analysis in a
50:50 split. For the MALDI based workflow, these frac-
tions were injected in the HPLC loading buffer onto a
100 μm×15 mm C18 Magic column (Auburn, Michrom
Bioresources, CA, USA) using a CapTrap pre-column
(Auburn, Michrom Bioresources, CA, USA). Mobile
phase A was 2% acetonitrile, 0.1% TFA, mobile phase B
was 85% acetonitrile, 5% n-PrOH, 10% water, 0.1%
TFA. HPLC elution was carried out at a 1-μL/min flow
rate on an Ultimate nanoHPLC workstation (Dionex-LC
Packings, Hercules, CA, USA). The HPLC elution from
the column was collected at 20-s intervals on the MALDI
plate using a Probot fraction collector (Dionex-LC Pack-
ings). Forty-eight-min HPLC elution was collected to the
MALDI plates as an array of 12× 12 sample spots. The
HPLC eluent was mixed with the MALDI matrix
(7.5 mg/mL α-cyano-4-hydroxycinnamic acid dissolved in
60:40 acetonitrile-water containing 0.15 mg/mL dibasic
ammonium-citrate) through a mixing tee (Upchurch, WA,
USA) at a flow rate of 2-μL/min. The most abundant,
middle-fractions of the SCX separation were spotted onto
two plates using a 90-min HPLC gradient.
MALDI plates were analyzed in automated mode on
the AB4700 Proteomics Analyzer (Applied Biosystems,
Framingham, MA, USA). First the MS spectra were col-
lected from the entire HPLC run. Then, using an in-
house developed program, MS/MS precursors were
selected by applying an exclusion algorithm to elimin-
ate: (a) redundant precursors carrying over multiple
HPLC fractions; and (b) using only the more abundant
members of peptide pairs for MS/MS analysis. MS/MS
spectra were acquired using up to 2,500 laser shots/pre-
cursor unless the predefined signal-to-noise level in the
MS/MS acquisitions was achieved sooner. The MS/MS
data were submitted for database searching as a batch
to Mascot (http://www.matrixscience.com) through its
automation interface of Mascot (Mascot Daemon). The
non-redundant NCBI protein database was used. A
detailed description of the acceptance criteria for the
database searching results will be described elsewhere.
In brief, tryptic peptides containing arginine residues
were accepted at a Mascot score >20, peptides not con-
taining arginine at a Mascot score >25. Peptides with
less-than-significant Mascot score were thoroughly
inspected, considering the correlation of peptide basicity
with SCX fraction numbers, presence of characteristic
high-energy CID fragments, and accurate mass mea-
surements through internal calibration of the MSspectra using the masses of confidently identified pep-
tides as internal mass references.
ESI based LC-MS/MS analyses were carried out using
an Ultimate nanoHPLC system (Dionex-LC Packings,
CA, USA) on a 75 μM×150 mm Picofrit C18 column
at a 300-nl/min flow rate with a gradient of 5% B to
30% B over 60 min. Mobile phase A was 2% acetonitrile,
0.1% formic acid, mobile phase was 85% acetonitrile, 5%
n-PrOH, 10% water, 0.1% formic. A CapTrap (Michrom
Bioresources, CA, USA) precolumn was used to precon-
centrate the sample.
A platinum electrode was placed behind the HPLC
column using a microtee (Upchurch, WA, USA) in order
to apply the electrospray voltage (3 kV) for LC-MS/MS
analysis. LC-MS/MS was performed using a QSTAR quad-
rupole time-of-flight instrument (Applied Biosystems, CA,
USA). The instrument was set up to perform a 1-s MS
scan (300–1500 Da) followed by three most abundant
components (two to four charges were allowed) exceed-
ing an intensity threshold of 35 counts. To improve the
protein coverage the samples were halved and the ana-
lysis was replicated. LC-MS and MS/MS analyses were
processed by the ProICAT software (Applied Biosystems,
Foster City, CA, USA). Database search results were
accepted at >95% confidence interval. Database searching
and quantification results from multiple MS platforms
were consolidated by parsing all the qualitative and quan-
titative peptide results into an Oracle database. The set
of all the identified peptides were assigned to a minimum
set of proteins that could explain all the confidently iden-
tified peptide sequences. The abundance ratios of peptide
pairs labeled with the heavy (9× 13C) and light (0× 13C)
ICATTM reagents were normalized to the median of all
peptide ratios in order to generate normalized expression
ratios. Expression ratios of peptides matching to the same
protein were averaged to generate expression ratios at
the protein level.
Statistical methods
Data are expressed as mean± SEM. Student’s t-test was
used to evaluate the differences of the means between
groups. Differences were considered significant at
P< 0.05. All analyses were performed using GraphPad
Prism software version 4.00 (GraphPad Software, San
Diego, CA, USA).Additional file
Additional file 1: Table S1. Identified and quantified proteins
involved in the splicing process
Competing interests
The authors declare that they have no competing interests.
Hallgren et al. Fibrogenesis & Tissue Repair 2012, 5:6 Page 12 of 13
http://www.fibrogenesis.com/content/5/1/6Acknowledgments
This work was supported by grants from the Swedish Medical Research
Council (11550), the Swedish Cancer Fund, the Swedish Society for Medical
Research, the Swedish Heart-Lung foundation the JA Persson, G Nilsson,
Greta and John Kock, A Österlund and Anna-Greta Crafoord Foundations,
Lars Hiertas Minne foundation, the Konsul Bergh Foundation, Riksföreningen
mot Rheumatism, the Royal Physiographic Society in Lund Gustaf V.s 80
Årsfond and the Medical Faculty, University of Lund. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Author details
1Department of Experimental Medical Science, Lund University, Lund,
Sweden. 2Department of Clinical Sciences, Lund, Lund University, Lund,
Sweden. 3Department of Immunotechnology, Lund University, Lund, Sweden.
4Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland. 5BG
Medicine, 610N Lincoln Street, Waltham, MA 02451, USA. 6Department of
Electrical Measurement, Lund University, Lund, Sweden.
Authors’ contributions
OH, JM, AAS, MW, LM, ET, PJ, GMV, and GWT conceived and designed the
experiments; OH, JM, LM, AAS, MW, GMV, and GWT performed the
experiments; OH, JM, LM, AAS, MW, GMV, and GWT analyzed the data; OH,
JM, LM, ET, GMV, PJ, and GWT contributed materials; OH, JM, AAS, and GWT
wrote the paper. All authors read and approved the final manuscript.
Received: 18 April 2011 Accepted: 28 April 2012
Published: 28 April 2012
References
1. James AL, Wenzel S: Clinical relevance of airway remodelling in airway
diseases. Eur Respir J 2007, 30:134–155.
2. Selman M, Pardo A: Idiopathic pulmonary fibrosis: an epithelial/
fibroblastic cross-talk disorder. Respir Res 2002, 3:3.
3. Gauldie J, Kolb M, Sime PJ: A new direction in the pathogenesis of
idiopathic pulmonary fibrosis? Respir Res 2002, 3:1.
4. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts
and mechano-regulation of connective tissue remodelling. Nat Rev Mol
Cell Biol 2002, 3:349–363.
5. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G:
The fibronectin domain ED-A is crucial for myofibroblastic phenotype
induction by transforming growth factor-beta1. J Cell Biol 1998, 142:873–881.
6. Leask A, Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB
J 2004, 18:816–827.
7. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine
UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor
type beta: rapid induction of fibrosis and angiogenesis in vivo and
stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986,
83:4167–4171.
8. Ignotz RA, Endo T, Massague J: Regulation of fibronectin and type I
collagen mRNA levels by transforming growth factor-beta. J Biol Chem
1987, 262:6443–6446.
9. Westergren-Thorsson G, Sarnstrand B, Fransson LA, Malmstrom A: TGF-beta
enhances the production of hyaluronan in human lung but not in skin
fibroblasts. Exp Cell Res 1990, 186:192–195.
10. Westergren-Thorsson G, Schmidtchen A, Sarnstrand B, Fransson LA,
Malmstrom A: Transforming growth factor-beta induces selective increase
of proteoglycan production and changes in the copolymeric structure of
dermatan sulphate in human skin fibroblasts. Eur J Biochem 1992,
205:277–286.
11. Hallgren O, Nihlberg K, Dahlback M, Bjermer L, Eriksson LT, Erjefalt JS,
Lofdahl CG, Westergren-Thorsson G: Altered fibroblast proteoglycan
production in COPD. Respir Res 2010, 11:55.
12. Nihlberg K, Andersson-Sjoland A, Tufvesson E, Erjefalt JS, Bjermer L,
Westergren-Thorsson G: Altered matrix production in the distal airways of
individuals with asthma. Thorax 2010, 65:670–676.
13. Andersson-Sjoland A, Thiman L, Nihlberg K, Hallgren O, Rolandsson S, Skog I,
Mared L, Hansson L, Eriksson L, Bjermer L, Westergren-Thorsson G:
Fibroblast phenotypes and their activity are changed in the wound
healing process after lung transplantation. J Heart Lung Transplant 2011,
30:945–954.14. Shepard PJ, Hertel KJ: The SR protein family. Genome Biol 2009, 10:242.
15. Graveley BR: Sorting out the complexity of SR protein functions. RNA
2000, 6:1197–1211.
16. Zahler AM, Lane WS, Stolk JA, Roth MB: SR proteins: a conserved family of
pre-mRNA splicing factors. Genes Dev 1992, 6:837–847.
17. Zahler AM, Neugebauer KM, Lane WS, Roth MB: Distinct functions of SR
proteins in alternative pre-mRNA splicing. Science 1993, 260:219–222.
18. Smith CW, Valcarcel J: Alternative pre-mRNA splicing: the logic of
combinatorial control. Trends Biochem Sci 2000, 25:381–388.
19. Caceres JF, Screaton GR, Krainer AR: A specific subset of SR proteins
shuttles continuously between the nucleus and the cytoplasm. Genes Dev
1998, 12:55–66.
20. Mermoud JE, Cohen PT, Lamond AI: Regulation of mammalian
spliceosome assembly by a protein phosphorylation mechanism. EMBO J
1994, 13:5679–5688.
21. Lin S, Xiao R, Sun P, Xu X, Fu XD: Dephosphorylation-dependent sorting of
SR splicing factors during mRNP maturation. Mol Cell 2005, 20:413–425.
22. Huang Y, Yario TA, Steitz JA: A molecular link between SR protein
dephosphorylation and mRNA export. Proc Natl Acad Sci U S A 2004,
101:9666–9670.
23. Balza E, Borsi L, Allemanni G, Zardi L: Transforming growth factor beta
regulates the levels of different fibronectin isoforms in normal human
cultured fibroblasts. FEBS Lett 1988, 228:42–44.
24. Lim LP, Sharp PA: Alternative splicing of the fibronectin EIIIB exon
depends on specific TGCATG repeats. Mol Cell Biol 1998, 18:3900–3906.
25. Han F, Gilbert JR, Harrison G, Adams CS, Freeman T, Tao Z, Zaka R, Liang H,
Williams C, Tuan RS, Norton PA, Hickok NJ: Transforming growth factor-
beta1 regulates fibronectin isoform expression and splicing factor SRp40
expression during ATDC5 chondrogenic maturation. Exp Cell Res 2007,
313:1518–1532.
26. Tufvesson E, Malmstrom J, Marko-Varga G, Westergren-Thorsson G: Biglycan
isoforms with differences in polysaccharide substitution and core protein
in human lung fibroblasts. Eur J Biochem 2002, 269:3688–3696.
27. Dours-Zimmermann MT, Zimmermann DR: A novel glycosaminoglycan
attachment domain identified in two alternative splice variants of
human versican. J Biol Chem 1994, 269:32992–32998.
28. Danielson KG, Fazzio A, Cohen I, Cannizzaro LA, Eichstetter I, Iozzo RV: The
human decorin gene: intron-exon organization, discovery of two
alternatively spliced exons in the 5’ untranslated region, and mapping of
the gene to chromosome 12q23. Genomics 1993, 15:146–160.
29. Pihlajaniemi T, Myllyla R, Seyer J, Kurkinen M, Prockop DJ: Partial
characterization of a low molecular weight human collagen that
undergoes alternative splicing. Proc Natl Acad Sci U S A 1987, 84:940–944.
30. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative
analysis of complex protein mixtures using isotope-coded affinity tags.
Nat Biotechnol 1999, 17:994–999.
31. Griffin TJ, Han DK, Gygi SP, Rist B, Lee H, Aebersold R, Parker KC: Toward a
high-throughput approach to quantitative proteomic analysis:
expression-dependent protein identification by mass spectrometry. J Am
Soc Mass Spectrom 2001, 12:1238–1246.
32. Smolka M, Zhou H, Aebersold R: Quantitative protein profiling using
two-dimensional gel electrophoresis, isotope-coded affinity tag labeling,
and mass spectrometry. Mol Cell Proteomics 2002, 1:19–29.
33. Michalickova K, Bader GD, Dumontier M, Lieu H, Betel D, Isserlin R, Hogue
CW: SeqHound: biological sequence and structure database as a
platform for bioinformatics research. BMC Bioinforma 2002, 3:32.
34. Barnard DC, Patton JG: Identification and characterization of a novel
serine-arginine-rich splicing regulatory protein. Mol Cell Biol 2000,
20:3049–3057.
35. Sanford JR, Bruzik JP: Regulation of SR protein localization during
development. Proc Natl Acad Sci U S A 2001, 98:10184–10189.
36. Malmstrom J, Larsen K, Hansson L, Lofdahl CG, Norregard-Jensen O,
Marko-Varga G, Westergren-Thorsson G: Proteoglycan and proteome profiling
of central human pulmonary fibrotic tissue utilizing miniaturized sample
preparation: a feasibility study. Proteomics 2002, 2:394–404.
37. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth
factor-beta 1 induces alpha-smooth muscle actin expression in
granulation tissue myofibroblasts and in quiescent and growing cultured
fibroblasts. J Cell Biol 1993, 122:103–111.
38. Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet 2002,
30:13–19.
Hallgren et al. Fibrogenesis & Tissue Repair 2012, 5:6 Page 13 of 13
http://www.fibrogenesis.com/content/5/1/639. Cooper TA, Mattox W: The regulation of splice-site selection, and its role
in human disease. Am J Hum Genet 1997, 61:259–266.
40. Kramer A: The structure and function of proteins involved in mammalian
pre-mRNA splicing. Annu Rev Biochem 1996, 65:367–409.
41. Teigelkamp S, Mundt C, Achsel T, Will CL, Luhrmann R: The human U5
snRNP-specific 100-kD protein is an RS domain-containing, putative RNA
helicase with significant homology to the yeast splicing factor Prp28p.
RNA 1997, 3:1313–1326.
42. Lauber J, Fabrizio P, Teigelkamp S, Lane WS, Hartmann E, Luhrmann R: The
HeLa 200 kDa U5 snRNP-specific protein and its homologue in
Saccharomyces cerevisiae are members of the DEXH-box protein family
of putative RNA helicases. EMBO J 1996, 15:4001–4015.
43. Valdez BC, Henning D, Busch RK, Woods K, Flores-Rozas H, Hurwitz J,
Perlaky L, Busch H: A nucleolar RNA helicase recognized by autoimmune
antibodies from a patient with watermelon stomach disease. Nucleic Acids
Res 1996, 24:1220–1224.
44. Guil S, Gattoni R, Carrascal M, Abian J, Stevenin J, Bach-Elias M: Roles of
hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing
regulation. Mol Cell Biol 2003, 23:2927–2941.
45. Long JC, Caceres JF: The SR protein family of splicing factors: master
regulators of gene expression. Biochem J 2009, 417:15–27.
46. Lin S, Fu XD: SR proteins and related factors in alternative splicing. Adv
Exp Med Biol 2007, 623:107–122.
47. Kuo BA, Uporova TM, Liang H, Bennett VD, Tuan RS, Norton PA: Alternative
splicing during chondrogenesis: modulation of fibronectin exon EIIIA
splicing by SR proteins. J Cell Biochem 2002, 86:45–55.
48. Cramer P, Caceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE, Kornblihtt
AR: Coupling of transcription with alternative splicing: RNA pol II
promoters modulate SF2/ASF and 9 G8 effects on an exonic splicing
enhancer. Mol Cell 1999, 4:251–258.
49. Lavigueur A, La Branche H, Kornblihtt AR, Chabot B: A splicing enhancer in
the human fibronectin alternate ED1 exon interacts with SR proteins and
stimulates U2 snRNP binding. Genes Dev 1993, 7:2405–2417.
50. Schwarzbauer JE, Tamkun JW, Lemischka IR, Hynes RO: Three different
fibronectin mRNAs arise by alternative splicing within the coding region.
Cell 1983, 35:421–431.
51. Xia P, Culp LA: Adhesion activity in fibronectin's alternatively spliced
domain EDa (EIIIA) and its neighboring type III repeats: oncogene-
dependent regulation. Exp Cell Res 1994, 213:253–265.
52. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM: Expression of
variant fibronectins in wound healing: cellular source and biological
activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994,
127:2037–2048.
53. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K: Deregulation of
alternative splicing of fibronectin pre-mRNA in malignant human liver
tumors. J Biol Chem 1989, 264:10331–10334.
54. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L: Transforming growth
factor-beta regulates the splicing pattern of fibronectin messenger RNA
precursor. FEBS Lett 1990, 261:175–178.
55. Malmstrom J, Larsen K, Malmstrom L, Tufvesson E, Parker K, Marchese J,
Williamson B, Patterson D, Martin S, Juhasz P, Westergren-Thorsson G,
Marko-Varga G: Nanocapillary liquid chromatography interfaced to
tandem matrix-assisted laser desorption/ionization and electrospray
ionization-mass spectrometry: mapping the nuclear proteome of human
fibroblasts. Electrophoresis 2003, 24:3806–3814.
doi:10.1186/1755-1536-5-6
Cite this article as: Hallgren et al.: Splicosomal and serine and arginine-
rich splicing factors as targets for TGF-β. Fibrogenesis & Tissue Repair 2012
5:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
